DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Yuen MF, Zhou X, Gane E. et al.
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
Lancet Gastroenterol Hepatol 2021;
6 (09) 723-732
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.